Product sales of both Vytorin and Zetia began falling almost because of this immediately. On Thursday, FDA said it got completed its review of the ultimate report on the study. The agency said outcomes showed that after two years of treatment, despite the fact that there was no difference in the thickness of plaque in the carotid artery in affected individual organizations that got either Vytorin or Zocor, there was a big change in cholesterol levels. Those in the Vytorin groups saw their level of poor, or LDL cholesterol, fall by 56 %, pitched against a 39 % drop in the Zocor group, FDA wrote in a statement. That big of a difference normally would be ‘a big deal,’ Brozak said. In its statement, the FDA wrote that, ‘Based on available data, patients should not end taking Vytorin or other cholesterol-lowering drugs and really should speak to their doctor or various other health care professional if they have any questions.’ The drugmakers’ joint venture issued a brief response repeating that statement.Recipients: Members and Personnel of the California Society of Health-System Pharmacists, Sacramento, CA. Award for Distinguished Leadership in Health-System Pharmacy Practice The Award for Distinguished Leadership in Health-Program Pharmacy Practice recognizes the contributions of practitioners who’ve achieved excellence in health-program pharmacy practice leadership. Recipient: Richard L. Lucarotti, Pharm.D., FASHP, Clinical Professor and Director of Experiential Education, Eugene Applebaum University of Pharmacy and Health Sciences, Wayne Condition University, Detroit, MI.